Forest Ray

The company showed early data establishing a rheumatoid arthritis-specific expression signature and is enrolling patients into a larger study.

The University of Notre Dame spinout has developed molecular subtyping tests for colorectal and other cancers, and seeks partners to bring them to the clinic.

The firm is preparing to expand a whole-exome sequencing pilot study, while pushing forward several other pan-African cancer research initiatives.

While year-over-year testing services declined, CareDx said recently completed studies, new drugs, and further payor coverage may drive growth.

Myriad's total revenue grew 23 percent year over year, driven by a strong quarter for hereditary cancer and prenatal testing.

The GenoVA study will follow participants for two years, comparing time to diagnosis and diagnostic test use between patients with and without PRS-informed care.

The Together for CHANGE initiative aims to build the largest African ancestry genomic database while supporting the communities from which it is recruiting.

A five-year, $4.6 million NCI grant will help the researchers advance their EFIRM electric field-based DNA detection platform toward potential regulatory approval.

A new study has found that common metrics used to evaluate PRS may overstate the scores' performance, as clinically focused metrics show more modest results.

A study by researchers at Johns Hopkins and the Canadian Cancer Trials Group demonstrated that early molecular therapy response correlated well with radiographic findings.